Cancer vaccines at an inflexion point: what next?
Cancer vaccines at an inflexion point: what next?
复制标题
DOI：
10.1186/1479-5876-9-148
复制
发表时间：
2011-09-09
影响因子：
7.4
通讯作者：
Marincola FM
中科院分区：
文献类型：
--
作者：
Bot A;Obrocea M;Marincola FM
随着兽医和人类使用的第一批治疗性癌症疫苗的批准，该领域在经历了相当长一段时间的动荡研究和开发之后，达到了一个重要的里程碑。由于这类药物的作用机制和临床益处与传统或小型靶向治疗癌症截然不同，仍有许多障碍需要克服，以充分释放其潜力。这些挑战和努力在刚刚出版的一本关于这个主题的书中得到了说明，这本书没有详尽但具有代表性地概述了癌症疫苗技术在不同发展阶段的最新进展。从癌症疫苗和其他免疫干预措施的临床测试中获得的主要经验教训正在被整合到新颖的尖端平台技术中，这些技术模糊了被动免疫疗法和主动免疫疗法之间的区别，并有望从根本上改变和改善癌症患者的管理。
With the approval of the first therapeutic cancer vaccines for veterinarian and human use, the field reached a significant milestone after a considerable interval of tumultuous research and development marked by numerous ups and downs. As the mechanism of action and clinical benefit afforded by this class of agents are starkly different from that of conventional or small targeted therapies for cancer, there are still numerous hurdles that need to be overcome to fully unleash their potential. These challenges and efforts are illustrated in a book just published on this subject, a non-exhaustive yet representative synopsis of the latest advances in cancer vaccine technologies in various stages of development. Major lessons resulting from clinical testing of cancer vaccines and other immune interventions, are being integrated in novel, cutting edge platform technologies that blur the distinction between passive and active immunotherapies as well as carry the promise of fundamentally changing and improving the management of patients with cancer.
登录
查看更多内容
小鼠外周淋巴器官中新型细胞类型的鉴定。 I.形态，定量，组织分布。
影响因子：
15.3
作者：
Steinman, R M;Cohn, Z A
通讯作者：
Cohn, Z A
影响因子：
64.8
作者：
ZINKERNA.RM;DOHERTY, PC
通讯作者：
DOHERTY, PC
DOI：
10.1073/pnas.91.9.3515
发表时间：
1994-04-26
影响因子：
11.1
作者：
KAWAKAMI, Y;ELIYAHU, S;ROSENBERG, SA
通讯作者：
ROSENBERG, SA
影响因子：
56.9
作者：
VANDERBRUGGEN, P;TRAVERSARI, C;BOON, T
通讯作者：
BOON, T
影响因子：
--
作者：
BURNET, M
通讯作者：
BURNET, M